Zhang Xingshu, Yin Wen, Guo Youwei, He Yi, Jiang Zhipeng, Li Yuzhe, Xie Bo, Zhang Seng, Jiang Xingjun, Liu Qing, Yuan Jian
Department of Neurosurgery, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Institute of Skull Base Surgery and Neuro-Oncology at Hunan, Changsha, China.
Front Oncol. 2022 Nov 3;12:1013419. doi: 10.3389/fonc.2022.1013419. eCollection 2022.
Rosai-Dorfman disease (RDD) is a rare benign non-Langerhans cell histiocytic proliferative disease. RDD with central nervous system (CNS) involvement (CNS-RDD) is extremely rare. Its etiology is unclear, and there are no consensus recommendations for its treatment. More studies are needed to elucidate the clinical and radiological manifestations and prognosis of CNS-RDD.
From January 2012 to June 2022, 12 patients with CNS-RDD (intracranial or spinal) were retrospectively evaluated, including collecting clinical data, imaging data, and pathological findings; summarizing imaging characteristics; and conducting follow-up studies on CND-RDD patient treatment and prognosis.
Twelve CNS-RDD patients (nine male and three female patients, aged 12-67 years) were enrolled in this study. Nine patients represented convex and/or skull base RDD (eight with edema, six with lobulation and/or pseudopodium sign, four with multiple intracranial lesions), two patients had parenchymal RDD, and one patient had spinal cord subdural lesions. Symptoms of patients would vary according to the locations of the lesion, including but not limited to headaches, dizziness, seizures, cranial nerve dysfunction, and visual impairment. The immunohistochemistry of RDD showed positive expression of S100 and CD68 but not CD1a. Total resection ( = 7), subtotal resection ( = 3), partial resection ( = 1), and stereotaxic biopsy ( = 1) were achieved, respectively. A combination of chemotherapy plus steroid therapy was performed on two patients (relapsing case and residual lesion) and showed a remarkable effect.
CNS-RDD, as a rare disease, presents a significant diagnostic challenge for clinicians. Solitary CNS-RDD are easily misdiagnosed as meningioma. However, when the MRI imaging of the disease represents dura-based masses with significant edema, homogeneous enhancement, lobulation, and/or pseudopodium sign, we should consider it might be the CNS-RDD. Surgery is an important and effective therapy for CNS-RDD. Steroids and chemotherapy are safe and effective for the postoperative treatment of relapsing cases or residual lesions.
罗萨伊-多夫曼病(RDD)是一种罕见的良性非朗格汉斯细胞组织细胞增生性疾病。累及中枢神经系统(CNS)的RDD(CNS-RDD)极为罕见。其病因尚不清楚,对于其治疗也没有共识性建议。需要更多研究来阐明CNS-RDD的临床、影像学表现及预后。
回顾性评估2012年1月至2022年6月期间12例CNS-RDD(颅内或脊髓)患者,包括收集临床资料、影像资料及病理结果;总结影像特征;并对CND-RDD患者的治疗及预后进行随访研究。
本研究纳入12例CNS-RDD患者(9例男性和3例女性患者,年龄12 - 67岁)。9例表现为凸面和/或颅底RDD(8例有水肿,6例有分叶和/或伪足征,4例有多发颅内病变),2例为实质型RDD,1例有脊髓硬膜下病变。患者症状会因病变部位而异,包括但不限于头痛、头晕、癫痫发作、颅神经功能障碍和视力损害。RDD的免疫组化显示S100和CD68呈阳性表达,但CD1a呈阴性。分别实现了全切除( = 7)、次全切除( = 3)、部分切除( = 1)和立体定向活检( = 1)。2例患者(复发病例和残留病变)接受了化疗加类固醇治疗,效果显著。
CNS-RDD作为一种罕见疾病,给临床医生带来了重大的诊断挑战。孤立性CNS-RDD易被误诊为脑膜瘤。然而,当该疾病的MRI影像表现为以硬脑膜为基底的肿块,伴有明显水肿、均匀强化、分叶和/或伪足征时,应考虑可能是CNS-RDD。手术是治疗CNS-RDD的重要且有效方法。类固醇和化疗对于复发病例或残留病变的术后治疗安全有效。